In today’s recent session, 8.09 million shares of the Pliant Therapeutics Inc (NASDAQ:PLRX) have been traded, and its beta is 1.07. Most recently the company’s share price was $3.14, and it changed around -$4.65 or -59.70% from the last close, which brings the market valuation of the company to $191.04M. PLRX at last check was trading at a discount to its 52-week high of $18.00, offering almost -473.25% off that amount. The share price’s 52-week low was $7.18, which indicates that the recent value has fallen by an impressive -128.66% since then. We note from Pliant Therapeutics Inc’s average daily trading volume that its 10-day average is 1.01 million shares, with the 3-month average coming to 640.79K.
Pliant Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.17. If we narrow it down even further, the data shows that 0 out of 14 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 1 recommended PLRX as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Pliant Therapeutics Inc is expected to report earnings per share of -0.98 for the current quarter.
Pliant Therapeutics Inc (NASDAQ:PLRX) trade information
Instantly PLRX has been showing red trend so far today with a performance of -59.70% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 12.88 on recent trading dayincreased the stock’s daily price by 75.62%. The company’s shares are currently down -76.16% year-to-date, but still down -71.92% over the last five days. On the other hand, Pliant Therapeutics Inc (NASDAQ:PLRX) is -75.10% down in the 30-day period. We can see from the shorts that 7.54 million shares have been sold at a short interest cover period of 13.44 day(s).
The consensus price target as assigned by Wall Street analysts is $35.5, which translates to bulls needing to increase their stock price by 91.15% from its current value. Analyst projections state that PLRX is forecast to be at a low of $33 and a high of $38.
Pliant Therapeutics Inc (PLRX) estimates and forecasts
The year-over-year growth rate is expected to be -100.00%, down from the previous year.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -22.68%. Pliant Therapeutics Inc earnings are expected to increase by -32.10% in 2025, but the outlook is negative -13.84% per year for the next five years.
PLRX Dividends
Pliant Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Pliant Therapeutics Inc (NASDAQ:PLRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.29% of Pliant Therapeutics Inc shares, and 111.95% of them are in the hands of institutional investors. The stock currently has a share float of 115.76%. Pliant Therapeutics Inc stock is held by 238.0 institutions, with DEEP TRACK CAPITAL, LP being the largest institutional investor. By 2024-06-30, it held 9.9238% of the shares, which is about 5.97 million shares worth $64.2 million.
BLACKROCK INC., with 8.2612% or 4.97 million shares worth $53.45 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Price (T.Rowe) New Horizons Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Sep 30, 2024. The former held 2.41 shares worth $7.39 million, making up 3.97% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.03 shares worth around $6.21 million, which represents about 3.34% of the total shares outstanding.
